Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 15.36% and Operating profit at 18.33% over the last 5 years
2
The company has declared Negative results for the last 5 consecutive quarters
3
With ROE of 4.80%, it has a fair valuation with a 1.73 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,526 Million (Small Cap)
36.00
NA
0.00%
-0.42
6.38%
1.13
Revenue and Profits:
Net Sales:
218 Million
(Quarterly Results - Dec 2025)
Net Profit:
34 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.25%
0%
-6.25%
6 Months
-13.54%
0%
-13.54%
1 Year
-2.41%
0%
-2.41%
2 Years
10.7%
0%
10.7%
3 Years
-44.65%
0%
-44.65%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
GemPharmatech Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
15.36%
EBIT Growth (5y)
18.33%
EBIT to Interest (avg)
41.84
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.44
Sales to Capital Employed (avg)
0.30
Tax Ratio
9.02%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.99%
ROE (avg)
6.83%
Valuation key factors
Factor
Value
P/E Ratio
36
Industry P/E
Price to Book Value
1.73
EV to EBIT
30.35
EV to EBITDA
14.85
EV to Capital Employed
2.39
EV to Sales
3.81
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
7.88%
ROE (Latest)
4.80%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
217.70
199.60
9.07%
Operating Profit (PBDIT) excl Other Income
44.30
33.60
31.85%
Interest
0.00
1.70
-100.00%
Exceptional Items
0.00
1.80
-100.00%
Consolidate Net Profit
34.50
39.00
-11.54%
Operating Profit Margin (Excl OI)
203.30%
168.20%
3.51%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 9.07% vs -1.82% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -11.54% vs -4.65% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
793.30
682.90
16.17%
Operating Profit (PBDIT) excl Other Income
164.60
188.40
-12.63%
Interest
0.00
4.50
-100.00%
Exceptional Items
0.00
2.30
-100.00%
Consolidate Net Profit
144.40
109.80
31.51%
Operating Profit Margin (Excl OI)
207.40%
134.00%
7.34%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 16.17% vs 10.23% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 31.51% vs -30.90% in Dec 2024
About GemPharmatech Co., Ltd. 
GemPharmatech Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






